SCHEMBL3353121

SCHEMBL3353121

O=C(O)N(O)CCCNCc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.62
HDAC3 O15379 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
TMEM97 Q5BJF2 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
KDM6B O15054 1/20 0.45
KDM4A O75164 1/20 0.45
KDM2A Q9Y2K7 1/20 0.45
PTPRF P10586 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN11 Q06124 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL3905099 0.92 MEN1 (0.55) CHRM2HDAC3HDAC1HDAC2HDAC8
SCHEMBL3356470 0.80 CHRM2 (0.56) CHRM2HDAC3HDAC1HDAC2HDAC8
SCHEMBL10045277 0.79 CHRM2 (0.90) CHRM2HDAC3HDAC1HDAC2HDAC8
SCHEMBL9297275 0.79 HDAC3 (0.73) CHRM2HDAC3HDAC1HDAC2HDAC8
SCHEMBL3119525 0.78 CHRM2 (0.70) CHRM2HDAC3HDAC1HDAC2HDAC8
SCHEMBL11597593 0.77 CHRM2 (0.79) CHRM2HDAC3HDAC1HDAC2HDAC8
Toluene SCHEMBL3916489 0.77 CHRM2 (0.51) CHRM2HDAC3HDAC1HDAC2HDAC8
SCHEMBL3351112 0.77 KDM6B (0.46) HDAC3HDAC1HDAC2HDAC8MEN1
SCHEMBL3357890 0.77 CHRM2 (0.59) CHRM2MEN1KMT2ASIGMAR1KDM6B
Acetic Acid SCHEMBL9334204 0.76 CHRM2 (0.63) CHRM2HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CHRM2 876/4885HDAC3 527/4885HDAC1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.